Funding Announcements

"As we look to further scale the business in the months and years ahead, the support from Scottish Enterprise will enable us to grow the team to keep apace with our strategic growth plans. We are building a fantastic team at Care Sourcer and we’re excited at the prospect of even more talented people joining the fold as we look to fix the broken care system in this country."

"Since its inception, Clyde Biosciences has been working hard to meet our clients’ needs in improving outcomes in drug development. This investment, led by Epidarex Capital, will help propel Clyde Biosciences to a new level, allowing us to strengthen our team, reinforce our commercial offering and broaden our geographic reach. We welcome the support of our investment partners and look forward to an exciting future."

"Parkwalk are delighted to continue to support the ground breaking technology from Dr Ken Smith’s laboratory at Addenbrookes, which enables the prognosis of IBD and an earlier clinical decision as to the correct drug treatment. This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune have done a magnificent job in productising the technology and are now taking the tests on their commercial pathway. We look forward to seeing the platform extended to benefit clinical outcomes in further diseases."

"We’re delighted to welcome our new corporate and VC investors from Japan and China, as well as having the continued strong support of our existing investors, who together form a world-class group that will help scale CTT quickly to exploit the market opportunity for its technology. CTT has grown rapidly over the last several years, and we’re looking forward to being able to continue executing on our growth plan and sharpening our commercialization focus within the consumer electronics, automotive and industrial markets. The partners we have and the injection of new capital means we can expect to enable our customers to begin rolling out the technology at scale in the near future."

"Many people living with cancer feel isolated and unsupported, and traditional routes of delivering healthcare struggle to address these issues. It’s also imperative that we gather the necessary data to understand how cancer therapies affect not just survival, but quality of life, so that patients and doctors can weigh up this information to make informed decisions about their care. At Vine, our goal is to put patients back in control."